What is Neuroversion?
Neuroversion operates at the intersection of neurology and interventional medicine, providing targeted solutions for patients suffering from complex conditions such as Long COVID, ME/CFS, and POTS. By prioritizing nerve-resetting procedures, the company effectively targets the physiological source of pain. This methodology represents a significant departure from conventional opioid-based pain management, positioning Neuroversion as a disruptive force in the healthcare sector. Their commitment to research-backed, innovative treatment options ensures that they remain at the forefront of clinical pain management, offering a sustainable alternative for long-term patient relief.
How much funding has Neuroversion raised?
Neuroversion has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Neuroversion
PPP
Public-Private Partnership
What's next for Neuroversion?
With the infusion of this latest capital, Neuroversion is expected to accelerate its clinical research initiatives and expand its service delivery infrastructure. The company is likely to focus on scaling its interventional procedures to reach a broader patient demographic, while simultaneously investing in the development of proprietary nerve-resetting technologies. As the firm transitions through this late-stage growth phase, the strategic focus will remain on establishing clinical efficacy and securing a dominant market position within the specialized pain management landscape. Future milestones will likely involve the integration of advanced diagnostic tools to further refine their patient-centric treatment protocols.
See full Neuroversion company page
